Nya data från fas 2-studien LEGATO-HD med laquinimod i Huntingtons sjukdom presenteras på den internationella kongressen ”Parkinson’s disease and movement disorders”

 

Magnetic Resonance Spectroscopy Evaluation of Neuronal Integrity and Astrocytosis in a Phase 2 Study of Laquinimod as a Treatment for Huntington Disease (LEGATO-HD)
Blair R. Leavitt, Ralf Reilmann, Mark Forrest Gordon, Karen E. Anderson, Andrew Feigin, Sarah J. Tabrizi, Julie C. Stout, Paola Piccini, Bretta Russell-Schulz, Alex L. Mackay, Beth Borowsky, Gail Rynkowski, Rita Volkinshtein, Juha-Matti Savola, Michael R. Hayden

Läs abstraktet här och hela postern här.

 

Brain MRI Volume Changes after 12 months laquinimod treatment of Huntington disease (LEGATO-HD)
Ralf Reilmann, Mark Forrest Gordon, Karen E. Anderson, Andrew Feigin, Sarah J. Tabrizi5, Blair R. Leavitt, Julie C. Stout, Paola Piccini, Nicola Hobbs, Richard Manber, Beth Borowsky, Gail Rynkowski, Rita Volkinshtein, Juha-Matti Savola and Michael Hayden

Läs abstraktet här och hela postern här.

 

Quantitative Motor (Q-Motor) Assessments Suggest a Beneficial Central Effect of Laquinimod in a Phase II Study in Huntington Disease (LEGATO-HD)
Ralf Reilmann, Mark Forrest Gordon, Robin Schubert, Karen E. Anderson, Andrew Feigin, Sarah J. Tabrizi, Blair R. Leavitt, Julie C. Stout, Paola Piccini, Beth Borowsky, Gail Rynkowski, Rita Volkinshtein, Juha-Matti Savola, Michael R. Hayden

Läs abstraktet här och hela postern här.